Get started
ELI LILLY AND COMPANY CEDEAR EACH 4 REPR 1 ORD NPV (USD)ELI LILLY AND COMPANY CEDEAR EACH 4 REPR 1 ORD NPV (USD)ELI LILLY AND COMPANY CEDEAR EACH 4 REPR 1 ORD NPV (USD)

ELI LILLY AND COMPANY CEDEAR EACH 4 REPR 1 ORD NPV (USD)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Seasonals Bonds

LLYC trade ideas

ELI LILLY Is starting its next big rally.Eli Lilly (LLY) is about to test its 1W MA50 (blue trend-line) following a rebound just below the 1W MA100 (green trend-line). The latter, has been the ultimate market Support since May 2018 (last time it broke below it). The overall correction since the July 15 2024 High seems like a Bull Flag pattern, no different than all the others after 2018 which only served as healthy rebalancing of an overbought price action. Based on he 1W RSI in particular and the Bullish Divergence it displayed, the current Bull Flag resembles more the March - October 2019 pattern. Both that and the next one reached their 2.0 Fibonacci extensions. As a result, our long-term Target on LLY is just below the 2.0 Fib at $1300. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
Eli Lillly $LLYNYSE:LLY – Long Setup Ahead of June FOMC Eli Lilly remains fundamentally strong, with robust growth in revenue (+45% YoY), driven by weight-loss and diabetes drugs like Mounjaro and Zepbound. Despite this, the stock saw a recent pullback after a lowered FY25 profit outlook. Technical View: LLY is trading near a key support zone around $710. The setup offers a favorable 1:5 risk/reward ratio, with a stop at $700.86 and a target near $768. Bollinger Bands are tightening, indicating a potential breakout. This decline could be partially driven by market caution ahead of the upcoming FOMC meeting in June. If support holds, we may see a bounce toward the $760–770 area. Plan: Entry: ~$710 Target: ~$768 Stop: ~$700.86 Risk/Reward: 1:5 Watching price action closely near the lower Bollinger band.
NYSE:LLYLong
by ALVO13_official
LLY Daily: Navigating Key Levels - Two Strategic OpportunitiesOVERVIEW: LLY has recently undergone a significant correction from its highs, finding strong demand at a crucial support zone. Price action now presents two distinct, high-probability long entry scenarios based on the stock's interaction with key horizontal levels. My analysis outlines potential entry points, clear targets, and risk management. KEY OBSERVATIONS & MARKET STRUCTURE: Major Demand Zone Established: Following a notable pullback in early May, LLY found substantial buying interest within the lower green horizontal zone (approximately $680 - $710). This area has acted as a robust "Support Trade" zone, preventing further downside and initiating a corrective bounce. Corrective Rally & Intermediate Resistance: From this strong support, LLY mounted a decent rally, completing a clear W-formation or basing pattern (highlighted by the orange and blue zig-zag lines). Price is currently interacting with an intermediate resistance level / supply zone (the upper grey/light green horizontal zone around $755 - $775). This level represents a critical point of contention between buyers and sellers. Two Strategic Entry Scenarios: The current market context offers two distinct long entry approaches, each with its own risk/reward profile: Scenario 1: Breakout Trade (Orange Ellipse / "1st Entry Above 775") A. Condition: This strategy focuses on a decisive breakout and sustained close above the current intermediate resistance level (approx. $775). A strong daily candle closing above this zone would confirm bullish momentum. B. Entry: Look for price action to confirm the breakout, potentially on a retest of the broken resistance now acting as support (as indicated by the orange arrow and ellipse). An entry above $775 is targeted here. C. Risk Management: A stop-loss should be placed just below the breakout level and the recent swing low, ideally around $745.33 (bottom of the red box). Scenario 2: Support Trade (Blue Ellipse / "2nd Entry 710") A. Condition: This strategy anticipates a potential rejection from the current intermediate resistance, leading to a pullback to the primary demand zone (approx. $710). B. Entry: Look for strong bullish reversal signals (e.g., bullish engulfing candle, hammer, demand zone rejection) if price retraces to the lower demand zone around $710 (indicated by the blue arrow and ellipse). This offers a potentially lower risk entry with a better risk-to-reward ratio for the same targets. C. Risk Management: A stop-loss would be positioned just below the main support zone, around $675.70 (bottom of the larger red box). POTENTIAL TARGETS: Regardless of the entry scenario, our upside targets remain consistent based on prior price structure and supply zones: • 1st Target: $860 (Green Zone): This is a significant resistance level from earlier price action, representing the first major hurdle for buyers. • 2nd Target: $920 (Upper Green Zone): This represents the ultimate upside target, aligning with the previous all-time highs and a major supply zone. INVALIDATION: • For "Breakout Trade" (1st Entry): A sustained daily close below $745.33 would invalidate this specific trade idea. • For "Support Trade" (2nd Entry): A sustained daily close below $675.70 would invalidate the entire bullish bias derived from the primary demand zone and suggest further downside is likely. CONCLUSION: LLY is presenting clear technical setups after finding substantial support. Traders can opt for an aggressive Breakout Trade if momentum sustains through intermediate resistance, or a more conservative Support Trade if price retraces to the established demand zone. Both strategies aim for significant upside potential towards $860 and $920, with clearly defined risk management levels. Risk Management is Paramount : Always adhere to your stop-loss and position sizing to protect your capital. This is not financial advice; do your own research. Disclaimer: The information provided in this chart is for educational and informational purposes only and should not be considered as investment advice. Trading and investing involve substantial risk and are not suitable for every investor. You should carefully consider your financial situation and consult with a financial advisor before making any investment decisions. The creator of this chart does not guarantee any specific outcome or profit and is not responsible for any losses incurred as a result of using this information. Past performance is not indicative of future results. Use this information at your own risk. This chart has been created for my own improvement in Trading and Investment Analysis. Please do your own analysis before any investments.
NYSE:LLYLong
by ManiMarkets
Eli Lilly Stock Down 10.9% Over Past YearTop or Consolidation? Here's My Take... It's not crystal clear — I can see the case for both. But after years of chart-watching, this doesn't quite look like a top to me: • Lacks symmetry • Had chances to break down, but no real follow-through 🧭 Where are we headed? I think pressure remains, and we could dip toward the 50% retracement of the 2023 move — that’s around 646. 🔁 If we bounce from there, I’ll shift my bias to a recovery and resumption of the long-term uptrend. Disclaimer: The information posted on Trading View is for informative purposes and is not intended to constitute advice in any form, including but not limited to investment, accounting, tax, legal or regulatory advice. The information therefore has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. Opinions expressed are our current opinions as of the date appearing on Trading View only. All illustrations, forecasts or hypothetical data are for illustrative purposes only. The Society of Technical Analysts Ltd does not make representation that the information provided is appropriate for use in all jurisdictions or by all Investors or other potential Investors. Parties are therefore responsible for compliance with applicable local laws and regulations. The Society of Technical Analysts will not be held liable for any loss or damage resulting directly or indirectly from the use of any information on this site.
NYSE:LLY
by The_STA
Can Lilly Redefine Weight Loss Market Leadership?Eli Lilly is rapidly emerging as a dominant force in the burgeoning weight loss drug market, presenting a significant challenge to incumbent leader Novo Nordisk. Lilly has demonstrated remarkable commercial success despite its key therapy, Zepbound (tirzepatide), entering the market well after Novo Nordisk's Wegovy (semaglutide). Zepbound's substantial revenue in 2024 underscores its rapid adoption and strong competitive standing, leading market analysts to project Eli Lilly's obesity drug sales will surpass Novo Nordisk's within the next few years. This swift ascent highlights the impact of a highly effective product in a market with immense unmet demand. The success of Eli Lilly's tirzepatide, the active ingredient in both Zepbound and the diabetes treatment Mounjaro, stems from its dual mechanism targeting GLP-1 and GIP receptors, offering potentially enhanced clinical benefits. The company's market position was further solidified by a recent U.S. federal court ruling that upheld the FDA's decision to remove tirzepatide from the drug shortage list. This legal victory effectively halts compounding pharmacies from producing unauthorized, cheaper versions of Zepbound and Mounjaro, thereby protecting Lilly's market exclusivity and ensuring the integrity of the supply chain for the approved product. Looking ahead, Eli Lilly's pipeline includes the promising oral GLP-1 receptor agonist, orforglipron. Positive Phase 3 trial results indicate its potential as a convenient, non-injectable alternative with comparable efficacy to existing therapies. As a small molecule, orforglipron offers potential advantages in manufacturing scalability and cost, which could significantly expand access globally if approved. Eli Lilly is actively increasing its manufacturing capacity to meet anticipated demand for its incretin therapies, positioning itself to capitalize on the vast and growing global market for weight management solutions.
NYSE:LLYLong
by UDIS_View
Eli Lilly (LLY) Shares Fall Over 15% in MayEli Lilly (LLY) Shares Fall Over 15% in May The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment: → From its April low to high, LLY shares rose by over 30%; → However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775. Why Are Eli Lilly (LLY) Shares Falling? The decline can be attributed to three key factors: 1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development. 2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares. 3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries. The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy. Technical Analysis: Eli Lilly (LLY) Share Chart Key price movements (marked on the chart) justify the formation of a downward channel. On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement. On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NYSE:LLY
by FXOpen
LLY possible buy trend This chart highlights a recent price breakout followed by a pullback into consolidation. Key indicators in play: ✅ EMA 9/20/56: Price is currently trading below all EMAs, showing fading momentum. The EMAs are curling down, suggesting short-term weakness or cooling after a strong move. 🟣 SMA 50 & 200: Price is sitting below both the 50-SMA and 200-SMA, indicating a bearish or neutral mid- to long-term setup. The flattening 200-SMA may act as a long-term base. 📉 VWAP (not shown but implied): Price is likely trading below VWAP, reinforcing the intraday bearish bias and low-volume consolidation. 📐 Support & Resistance Levels: Blue horizontal lines mark recent support/resistance flips, providing key zones to watch for a breakout or breakdown. 🧠 Outlook: Current price action suggests a cool-down after a vertical run-up, with EMAs potentially acting as short-term resistance. Watching for a bounce off horizontal support or a move above the EMAs to confirm trend continuation.
NYSE:LLYLong
by MyGolfBudget
Eli Lilly: Catch the Knife or Wait for Support?LLY Just Dropped — Opportunity or Trap? 🔥 LLY (Eli Lilly) is on every trader’s radar! With biotech momentum and blockbuster drug potential, this stock is ready to rip once the dust settles. Smart money is eyeing key zones for a golden entry. 💊📈 📉 New Entry Zones: 🔥 630.00 – Solid buy level 🔥 550.00 – Strong value zone 🔥 465.00 – Deep discount opportunity (load-up zone!) 🎯 Profit Targets: ✅ 730.00 📈 (First leg up) ✅ 800.00 🚀 (Breakout zone) ✅ 900.00+ 💰 (All-time high chase) 💡 Volatility creates opportunity. LLY is a beast in the pharma game—any dip could set up a powerful bounce. Watch for heavy accumulation and reversal signals near those buy zones! 🚀 Ready to ride the next wave? LLY’s runway is long and the upside is juicy! #LLY #PharmaStocks #BuyTheDip #GrowthPlays 📌 Disclaimer: Not financial advice. Do your own research and consult with a professional before investing. 🔎💼
NYSE:LLYLong
by Robert_V12
ELI LILLY: The time to buy and target 1,300 is now.Eli Lilly is neutral on its 1D technical outlook (RSI = 48.409, MACD = -5.160, ADX = 28.927) and this is technically the most efficient level to buy for the long term towards the end of the year, as the price is sitting around its 1W MA50. The macro pattern is a Channel Up starting back in March 2019 and every time this broke under the 1W MA50 (but remained supported above the 1W MA100) and consolidated, it was the most efficient long term buy signal. In 6 years this has only happened 4 times and all those times the 1W RSI hit the 38.750 S1 level. The immediate target of all bullish waves that started after such bottoms, has been the 2.0 Fibonacci extension. Go long, TP = 1,300. ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:LLYLong
by InvestingScope